Loading
Diabetes Treatment and Management · Journal article
European Journal of Preventive Cardiology · August 18, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing evidence that GLP-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes with elevated cardiovascular risk, that dual GIP/GLP-1 agonists offer more potent metabolic effects, and that GLP-1 therapies reduce cardiovascular events in non-diabetic obesity and may benefit selected heart failure with preserved ejection fraction patients. The review frames these as integrated metabolic, inflammatory, vascular, and hemodynamic effects, but does not report new primary data or pooled effect sizes.
Narrative review. Type 2 diabetes patients with elevated cardiovascular risk, non-diabetic patients with obesity, and selected patients with heart failure with preserved ejection fraction..
GLP-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes patients with elevated cardiovascular risk, with benefits extending beyond glycemic control. Dual GIP and GLP-1 receptor agonists achieve more potent metabolic effects and raise interest in cardiovascular implications. Pharmacologic treatment of obesity with GLP-1–based therapies reduces cardiovascular events in patients without diabetes.
Safety considerations mentioned but not elaborated in abstract. GLP-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes patients with elevated cardiovascular risk, with benefits extending beyond glycemic control.
Clinicians should recognize GLP-1 and dual GIP/GLP-1 agonists as cardiometabolic agents beyond glucose lowering, with evidence of cardiovascular benefit in diabetes, obesity, and emerging support in heart failure. The review signals expanding clinical applications across the cardiometabolic continuum, warranting consideration in risk stratification and treatment selection.
A narrative review synthesizing evidence on GLP-1 and GIP/GLP-1 therapies across cardiovascular disease, diabetes, obesity, and heart failure—providing expert synthesis rather than new primary data.
As stated by the source record.
Clinicians should recognize GLP-1 and dual GIP/GLP-1 agonists as cardiometabolic agents beyond glucose lowering, with evidence of cardiovascular benefit in diabetes, obesity, and emerging support in heart failure. The review signals expanding clinical applications across the cardiometabolic continuum, warranting consideration in risk stratification and treatment selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed as glucose-lowering therapies for type 2 diabetes mellitus but have progressively emerged as cardiometabolic agents with clinically relevant cardiovascular effects. Large cardiovascular outcome trials have demonstrated reductions in major adverse cardiovascular events in patients with type 2 diabetes and elevated cardiovascular risk, benefits that extend beyond glycemic control. In parallel, the development of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists has further expanded incretin-based therapy by achieving more potent metabolic effects, raising interest in their potential cardiovascular implications. More recently, pharmacologic treatment of obesity with GLP-1–based therapies has been shown to reduce cardiovascular events in patients without diabetes, while emerging evidence supports a role for these agents in selected populations with heart failure with preserved ejection fraction. These effects appear to reflect integrated metabolic, inflammatory, vascular, and hemodynamic mechanisms. This review summarizes current evidence on the cardiovascular effects of GLP-1 receptor agonists and dual GIP–GLP-1 receptor agonists, discusses safety considerations, and highlights future directions for their clinical application across the cardiometabolic continuum.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.